Board of Directors

Evan Rachlin, MD, is the co-founder and a Managing Partner of Ascenta Capital. He was previously a Managing Director at Blackstone Life Sciences from 2019 to 2022. Prior to Blackstone, he was Head of Strategy (reporting to the CEO) at Moderna (NASDAQ: MRNA) from 2015 to 2019, where he led development of the company’s annual long-range plan and helped formulate portfolio strategy and execute equity financings. He was a Principal at Bain Capital Ventures from 2012 to 2015, and began his career in New York City at McKinsey & Company and Pfizer.

Dr. Rachlin currently serves on the board of directors of Ascenta Portfolio companies Iambic Therapeutics, Cardurion Pharmaceuticals, OrsoBio, and Alpha-9 Oncology. He also serves on the board of Boston Children’s Hospital Trust, and he previously served on the boards of Fergene, Apixio, MedHOK, Boston Heart Diagnostics, and MedeAnalytics. He graduated from Harvard University, magna cum laude with an AB in Biochemistry and Japanese. He earned an M.D. from Harvard Medical School.